ES2545959T3 - Un medicamento consistente en un derivado de carboestirilo y donepezilo para el tratamiento de la enfermedad de Alzheimer - Google Patents

Un medicamento consistente en un derivado de carboestirilo y donepezilo para el tratamiento de la enfermedad de Alzheimer Download PDF

Info

Publication number
ES2545959T3
ES2545959T3 ES08764779.8T ES08764779T ES2545959T3 ES 2545959 T3 ES2545959 T3 ES 2545959T3 ES 08764779 T ES08764779 T ES 08764779T ES 2545959 T3 ES2545959 T3 ES 2545959T3
Authority
ES
Spain
Prior art keywords
carbostyril
donepezil
alzheimer
disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08764779.8T
Other languages
English (en)
Inventor
Heii Arai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Juntendo University
Original Assignee
Otsuka Pharmaceutical Co Ltd
Juntendo University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd, Juntendo University filed Critical Otsuka Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2545959T3 publication Critical patent/ES2545959T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un medicamento para uso en el tratamiento de la enfermedad de Alzheimer que tiene, como principios activos, un derivado de carboestirilo de fórmula general:**Fórmula** donde A es un grupo alquileno C1-6, R es un grupo cicloalquilo y la unión entre las posiciones 3 y 4 del esqueleto de carboestirilo es un enlace sencillo o un doble enlace, o una sal del mismo y donepezilo o una sal del mismo.

Description

imagen1
imagen2
imagen3
imagen4

Claims (1)

  1. imagen1
ES08764779.8T 2007-05-22 2008-05-21 Un medicamento consistente en un derivado de carboestirilo y donepezilo para el tratamiento de la enfermedad de Alzheimer Active ES2545959T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007135367 2007-05-22
JP2007135367 2007-05-22
PCT/JP2008/059763 WO2008143361A1 (en) 2007-05-22 2008-05-21 A medicament comprising a carbostyril derivative and donepezil for treating alzheimer's disease

Publications (1)

Publication Number Publication Date
ES2545959T3 true ES2545959T3 (es) 2015-09-17

Family

ID=39636992

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08764779.8T Active ES2545959T3 (es) 2007-05-22 2008-05-21 Un medicamento consistente en un derivado de carboestirilo y donepezilo para el tratamiento de la enfermedad de Alzheimer

Country Status (27)

Country Link
US (1) US20100298375A1 (es)
EP (2) EP2157973B1 (es)
JP (1) JP5153870B2 (es)
KR (1) KR101441725B1 (es)
CN (1) CN101754758B (es)
AR (1) AR066664A1 (es)
AU (1) AU2008253977B2 (es)
BR (1) BRPI0811919A2 (es)
CA (1) CA2687289C (es)
CO (1) CO6251249A2 (es)
CY (1) CY1116683T1 (es)
DK (1) DK2157973T3 (es)
ES (1) ES2545959T3 (es)
HR (1) HRP20150843T1 (es)
HU (1) HUE025902T2 (es)
IL (1) IL202053A (es)
MX (1) MX2009012583A (es)
MY (1) MY146407A (es)
NZ (1) NZ581099A (es)
PL (1) PL2157973T3 (es)
PT (1) PT2157973E (es)
RU (1) RU2469723C2 (es)
SI (1) SI2157973T1 (es)
TW (2) TWI489983B (es)
UA (1) UA96633C2 (es)
WO (1) WO2008143361A1 (es)
ZA (1) ZA200908202B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
RS57426B1 (sr) 2011-03-01 2018-09-28 Pharnext Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata
JP5715303B2 (ja) * 2012-06-15 2015-05-07 公益財団法人先端医療振興財団 軽度認知障害の予防および／または治療剤
US20160331922A1 (en) * 2013-12-23 2016-11-17 John W. Holaday Disposable container for air hydration
US20190142820A1 (en) 2016-05-19 2019-05-16 National Cerebral And Cardiovascular Center Drug for preventing and/or treating dementia
SG11201909895UA (en) 2017-05-24 2019-11-28 H Lundbeck As Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles
CN107602523B (zh) * 2017-09-11 2020-08-18 安徽中医药大学 京尼平类似物、制备方法及其应用
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5649378A (en) 1979-08-25 1981-05-02 Otsuka Pharmaceut Co Ltd Tetrazolylalkoxycarbostyril derivative
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2574099B2 (ja) 1992-05-21 1997-01-22 大塚製薬株式会社 アレルギー疾患治療剤
JPH10175864A (ja) 1996-12-16 1998-06-30 Otsuka Pharmaceut Co Ltd 慢性閉塞性肺疾患治療剤
US6019735A (en) * 1997-08-28 2000-02-01 Visco Technologies, Inc. Viscosity measuring apparatus and method of use
US6428488B1 (en) * 1997-08-28 2002-08-06 Kenneth Kensey Dual riser/dual capillary viscometer for newtonian and non-newtonian fluids
US6322525B1 (en) * 1997-08-28 2001-11-27 Visco Technologies, Inc. Method of analyzing data from a circulating blood viscometer for determining absolute and effective blood viscosity
US6322524B1 (en) * 1997-08-28 2001-11-27 Visco Technologies, Inc. Dual riser/single capillary viscometer
US6252081B1 (en) * 1998-01-16 2001-06-26 Eisai Co., Ltd. Process for production of donepezil derivative
US6187790B1 (en) * 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6484565B2 (en) * 1999-11-12 2002-11-26 Drexel University Single riser/single capillary viscometer using mass detection or column height detection
US6458804B1 (en) * 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
TW200301135A (en) * 2001-12-27 2003-07-01 Otsuka Maryland Res Inst Inc Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
IL150509A (en) * 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical preparations containing donafazil hydrochloride
US6743806B2 (en) * 2002-10-23 2004-06-01 Otsuka Pharmaceutical Company, Limited Active oxygen scavenger
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
JP2004189706A (ja) * 2002-12-13 2004-07-08 Eisai Co Ltd 高度アルツハイマー型痴呆治療剤
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener

Also Published As

Publication number Publication date
MY146407A (en) 2012-08-15
IL202053A (en) 2016-04-21
IL202053A0 (en) 2010-06-16
EP2157973B1 (en) 2015-07-15
AU2008253977B2 (en) 2013-08-22
EP2937085A1 (en) 2015-10-28
KR101441725B1 (ko) 2014-09-18
JP2010527993A (ja) 2010-08-19
TW200904428A (en) 2009-02-01
EP2157973A1 (en) 2010-03-03
CN101754758B (zh) 2012-10-24
MX2009012583A (es) 2010-03-08
US20100298375A1 (en) 2010-11-25
JP5153870B2 (ja) 2013-02-27
CA2687289C (en) 2015-09-15
DK2157973T3 (en) 2015-08-17
RU2009147456A (ru) 2011-06-27
PL2157973T3 (pl) 2015-12-31
BRPI0811919A2 (pt) 2014-11-18
TWI489983B (zh) 2015-07-01
CN101754758A (zh) 2010-06-23
RU2469723C2 (ru) 2012-12-20
HUE025902T2 (en) 2016-05-30
CO6251249A2 (es) 2011-02-21
NZ581099A (en) 2012-03-30
AU2008253977A1 (en) 2008-11-27
WO2008143361A1 (en) 2008-11-27
CA2687289A1 (en) 2008-11-27
HK1140422A1 (en) 2010-10-15
UA96633C2 (uk) 2011-11-25
TW201412315A (zh) 2014-04-01
TWI423802B (zh) 2014-01-21
EP2937085B1 (en) 2019-07-10
HK1215384A1 (en) 2016-08-26
HRP20150843T1 (hr) 2015-09-11
CY1116683T1 (el) 2017-03-15
AR066664A1 (es) 2009-09-02
SI2157973T1 (sl) 2015-10-30
ZA200908202B (en) 2010-07-28
KR20100020482A (ko) 2010-02-22
PT2157973E (pt) 2015-10-14

Similar Documents

Publication Publication Date Title
ES2545959T3 (es) Un medicamento consistente en un derivado de carboestirilo y donepezilo para el tratamiento de la enfermedad de Alzheimer
ES2557303T3 (es) Agente terapéutico para la estenosis del canal espinal
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
UY29633A1 (es) Derivados de oxindol
ES2488407T3 (es) Preparación farmacéutica que contiene lipasa de origen bacteriano
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
UA108363C2 (uk) Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
CL2008002542A1 (es) Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis.
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
AR076400A1 (es) Formulaciones liquidas de sales de 1-(2-(2,4-dimetilfenilsulfanil)fenil)piperazina, uso, la sal y recipiente
DOP2012000050A (es) Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina
CO2020000240A2 (es) Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico
CL2012000708A1 (es) Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades.
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
ES2531516T3 (es) Uso de escina
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
AR097997A1 (es) Composición farmaceutica de ibuprofeno y tramadol para uso oftálmico
ES2552654T3 (es) Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
ES2581331T3 (es) Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
AR067446A1 (es) Un medicamento para tratar higado graso que comprende cilostazol
ECSP10010464A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares
GT200600157A (es) Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo